{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:16:19Z","timestamp":1791270979437,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR-19.13"],"award-info":[{"award-number":["W.OR-19.13"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018748","name":"Argenx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005039","name":"Leids Universitair Medisch Centrum","doi-asserted-by":"publisher","award":["OIO"],"award-info":[{"award-number":["OIO"]}],"id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["VENI 0915016181 0040"],"award-info":[{"award-number":["VENI 0915016181 0040"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen","award":["LSHM18055-SGF"],"award-info":[{"award-number":["LSHM18055-SGF"]}]},{"name":"Top Sector Life Sciences & Health to Samenwerkende Gezondheidsfondsen","award":["LSHM19130"],"award-info":[{"award-number":["LSHM19130"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Muscle-specific kinase (MuSK) is crucial for acetylcholine receptor (AChR) clustering and thereby neuromuscular junction (NMJ) function. NMJ dysfunction is a hallmark of several neuromuscular diseases, including MuSK myasthenia gravis. Aiming to restore NMJ function, we generated several agonist monoclonal antibodies targeting the MuSK Ig-like 1 domain. These activated MuSK and induced AChR clustering in cultured myotubes. The most potent agonists partially rescued myasthenic effects of MuSK myasthenia gravis patient IgG autoantibodies in vitro. In an IgG4 passive transfer MuSK myasthenia model in NOD\/SCID mice, MuSK agonists caused accelerated weight loss and no rescue of myasthenic features. The MuSK Ig-like 1 domain agonists unexpectedly caused sudden death in a large proportion of male C57BL\/6 mice (but not female or NOD\/SCID mice), likely caused by a urologic syndrome. In conclusion, these agonists rescued pathogenic effects in myasthenia models in vitro<jats:italic>,<\/jats:italic> but not in vivo. The sudden death in male mice of one of the tested mouse strains revealed an unexpected and unexplained role for MuSK outside skeletal muscle, thereby hampering further (pre-) clinical development of these clones. Future research should investigate whether other Ig-like 1 domain MuSK antibodies, binding different epitopes, do hold a safe therapeutic promise.<\/jats:p>","DOI":"10.1038\/s41598-023-32641-1","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T19:01:49Z","timestamp":1683572509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK"],"prefix":"10.1038","volume":"13","author":[{"given":"Jamie L.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Augustinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Plomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Roya-Kouchaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L. E.","family":"Vergoossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Filli\u00e9-Grijpma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Struijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Salvatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Steyaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blanchetot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland","family":"Vanhauwaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Silence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re M.","family":"van der Maarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"32641_CR1","doi-asserted-by":"publisher","first-page":"8058","DOI":"10.3390\/ijms22158058","volume":"22","author":"SR Iyer","year":"2021","unstructured":"Iyer, S. R., Shah, S. B. & Lovering, R. M. The neuromuscular junction: Roles in aging and neuromuscular disease. Int. J. Mol. Sci. 22, 8058. https:\/\/doi.org\/10.3390\/ijms22158058 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32641_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14728222.2017.1369960","volume":"21","author":"K Ohno","year":"2017","unstructured":"Ohno, K., Ohkawara, B. & Ito, M. Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders. Expert Opin. Ther. Targets 21, 949\u2013958 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"32641_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"JC Deenen","year":"2015","unstructured":"Deenen, J. C., Horlings, C. G., Verschuuren, J. J., Verbeek, A. L. & van Engelen, B. G. The epidemiology of neuromuscular disorders: A comprehensive overview of the literature. J. Neuromuscul. Dis. 2, 73\u201385 (2015).","journal-title":"J. Neuromuscul. Dis."},{"key":"32641_CR4","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya, S. et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552\u20132569 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"32641_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.expneurol.2003.10.004","volume":"185","author":"LR Fischer","year":"2004","unstructured":"Fischer, L. R. et al. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 185, 232\u2013240 (2004).","journal-title":"Exp. Neurol."},{"key":"32641_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.molcel.2010.06.007","volume":"39","author":"E Bergamin","year":"2010","unstructured":"Bergamin, E., Hallock, P. T., Burden, S. J. & Hubbard, S. R. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol. Cell 39, 100\u2013109 (2010).","journal-title":"Mol. Cell"},{"key":"32641_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature11348","volume":"489","author":"N Yumoto","year":"2012","unstructured":"Yumoto, N., Kim, N. & Burden, S. J. Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 489, 438\u2013442 (2012).","journal-title":"Nature"},{"key":"32641_CR8","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1242\/dev.02696","volume":"133","author":"SD Weatherbee","year":"2006","unstructured":"Weatherbee, S. D., Anderson, K. V. & Niswander, L. A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 133, 4993\u20135000 (2006).","journal-title":"Development"},{"key":"32641_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0896-6273(00)80751-5","volume":"23","author":"RW Burgess","year":"1999","unstructured":"Burgess, R. W., Nguyen, Q. T., Son, Y. J., Lichtman, J. W. & Sanes, J. R. Alternatively spliced isoforms of nerve- and muscle-derived agrin: Their roles at the neuromuscular junction. Neuron 23, 33\u201344 (1999).","journal-title":"Neuron"},{"key":"32641_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","volume":"17","author":"TM DeChiara","year":"1996","unstructured":"DeChiara, T. M. et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 17, 501\u2013512 (1996).","journal-title":"Cell"},{"key":"32641_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/brain\/aws025","volume":"135","author":"R Klooster","year":"2012","unstructured":"Klooster, R. et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135, 1081\u20131101 (2012).","journal-title":"Brain"},{"key":"32641_CR12","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/mus.26025","volume":"57","author":"Z Li","year":"2018","unstructured":"Li, Z. et al. Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis. Muscle Nerve 57, 814\u2013820 (2018).","journal-title":"Muscle Nerve"},{"key":"32641_CR13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/hmg\/ddy054","volume":"27","author":"E O'Connor","year":"2018","unstructured":"O\u2019Connor, E. et al. MYO9A deficiency in motor neurons is associated with reduced neuromuscular agrin secretion. Hum. Mol. Genet. 27, 1434\u20131446 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"32641_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.15252\/emmm.201607298","volume":"9","author":"S Miyoshi","year":"2017","unstructured":"Miyoshi, S. et al. DOK7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol. Med. 9, 880\u2013889 (2017).","journal-title":"EMBO Mol. Med."},{"key":"32641_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbrc.2020.07.031","volume":"530","author":"KA Kaifer","year":"2020","unstructured":"Kaifer, K. A. et al. AAV9-DOK7 gene therapy reduces disease severity in Smn2B\/- SMA model mice. Biochem. Biophys. Res. Commun. 530, 107\u2013114 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"32641_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fncel.2018.00017","volume":"12","author":"M Boido","year":"2018","unstructured":"Boido, M. et al. Increasing agrin function antagonizes muscle atrophy and motor impairment in spinal muscular atrophy. Front. Cell. Neurosci. 12, 17. https:\/\/doi.org\/10.3389\/fncel.2018.00017 (2018).","journal-title":"Front. Cell. Neurosci."},{"key":"32641_CR17","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.1250744","volume":"19","author":"S Arimura","year":"2014","unstructured":"Arimura, S. et al. Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science 19, 1505\u20131508 (2014).","journal-title":"Science"},{"key":"32641_CR18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.celrep.2012.08.004","volume":"2","author":"MJ Perez-Garcia","year":"2012","unstructured":"Perez-Garcia, M. J. & Burden, S. J. Increasing MuSK activity delays denervation and improves motor function in ALS mice. Cell Rep. 2, 497\u2013502 (2012).","journal-title":"Cell Rep."},{"key":"32641_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1093\/hmg\/ddab135","volume":"30","author":"T Hui","year":"2021","unstructured":"Hui, T. et al. Increasing LRP4 diminishes neuromuscular deficits in a mouse model of Duchenne muscular dystrophy. Hum. Mol. Genet. 30, 1579\u20131590 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"32641_CR20","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nbt0897-768","volume":"15","author":"MH Xie","year":"1997","unstructured":"Xie, M. H., Yuan, J., Adams, C. & Gurney, A. Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv. Nat. Biotechnol. 15, 768\u2013771 (1997).","journal-title":"Nat. Biotechnol."},{"key":"32641_CR21","doi-asserted-by":"publisher","first-page":"e34375","DOI":"10.7554\/eLife.34375","volume":"7","author":"S Cantor","year":"2018","unstructured":"Cantor, S. et al. Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody. Elife 7, e34375. https:\/\/doi.org\/10.7554\/eLife.34375 (2018).","journal-title":"Elife"},{"key":"32641_CR22","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.3390\/ijms22158015","volume":"22","author":"Z Feng","year":"2021","unstructured":"Feng, Z. et al. Activation of muscle-specific kinase (MuSK) reduces neuromuscular defects in the Delta7 mouse model of spinal muscular atrophy (SMA). Int. J. Mol. Sci. 22, 8015. https:\/\/doi.org\/10.3390\/ijms22158015 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32641_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-021-03672-3","volume":"595","author":"J Oury","year":"2021","unstructured":"Oury, J. et al. Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia. Nature 595, 404\u2013408 (2021).","journal-title":"Nature"},{"key":"32641_CR24","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1212\/NXI.0000000000000547","volume":"21","author":"MG Huijbers","year":"2019","unstructured":"Huijbers, M. G. et al. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurol. Neuroimmunol. Neuroinflamm. 21, e547. https:\/\/doi.org\/10.1212\/NXI.0000000000000547 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"32641_CR25","doi-asserted-by":"publisher","first-page":"e2020635118","DOI":"10.1073\/pnas.2020635118","volume":"30","author":"DLE Vergoossen","year":"2021","unstructured":"Vergoossen, D. L. E. et al. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proc. Natl. Acad. Sci. USA 30, e2020635118. https:\/\/doi.org\/10.1073\/pnas.2020635118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32641_CR26","doi-asserted-by":"publisher","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","volume":"75","author":"M Hezareh","year":"2001","unstructured":"Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. & Parren, P. W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 75, 12161\u201312168 (2001).","journal-title":"J. Virol."},{"key":"32641_CR27","doi-asserted-by":"publisher","first-page":"18218","DOI":"10.1074\/jbc.274.26.18218","volume":"274","author":"HJ de Haard","year":"1999","unstructured":"de Haard, H. J., van Neer, N., Reurs, A., Hufton, S. E. & Roovers, R. C. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274, 18218\u201318230 (1999).","journal-title":"J. Biol. Chem."},{"key":"32641_CR28","doi-asserted-by":"publisher","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny, I., Cossins, J., Waters, P., Beeson, D. & Vincent, A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1\u20133 can disperse preformed agrin-independent AChR clusters. PLoS\u00a0One 8, e80695. https:\/\/doi.org\/10.1371\/journal.pone.0080695 (2013).","journal-title":"PLoS\u00a0One"},{"key":"32641_CR29","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1097\/00001756-200411150-00014","volume":"15","author":"ST Ngo","year":"2004","unstructured":"Ngo, S. T., Balke, C., Phillips, W. D. & Noakes, P. G. Neuregulin potentiates agrin-induced acetylcholine receptor clustering in myotubes. NeuroReport 15, 2501\u20132505 (2004).","journal-title":"NeuroReport"},{"key":"32641_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.expneurol.2014.12.013","volume":"270","author":"WD Phillips","year":"2015","unstructured":"Phillips, W. D. et al. Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis. Exp. Neurol. 270, 29\u201340 (2015).","journal-title":"Exp. Neurol."},{"key":"32641_CR31","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers, M. G. et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc. Natl. Acad. Sci. USA 110, 20783\u201320788 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32641_CR32","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","volume":"180","author":"S Mori","year":"2012","unstructured":"Mori, S. et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am. J. Pathol. 180, 798\u2013810 (2012).","journal-title":"Am. J. Pathol."},{"key":"32641_CR33","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF00199929","volume":"26","author":"RL Wahl","year":"1988","unstructured":"Wahl, R. L. et al. The intraperitoneal delivery of radiolabeled monoclonal antibodies: Studies on the regional delivery advantage. Cancer Immunol. Immunother. 26, 187\u2013201 (1988).","journal-title":"Cancer Immunol. Immunother."},{"key":"32641_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.yhbeh.2007.03.030","volume":"52","author":"EM Hull","year":"2007","unstructured":"Hull, E. M. & Dominguez, J. M. Sexual behavior in male rodents. Horm. Behav. 52, 45\u201355 (2007).","journal-title":"Horm. Behav."},{"key":"32641_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0031-9384(88)90355-1","volume":"44","author":"LA Elmore","year":"1988","unstructured":"Elmore, L. A. & Sachs, B. D. Role of the bulbospongiosus muscles in sexual behavior and fertility in the house mouse. Physiol. Behav. 44, 125\u2013129 (1988).","journal-title":"Physiol. Behav."},{"key":"32641_CR36","first-page":"456","volume-title":"Urinary System. Monographs on Pathology of Laboratory Animals","author":"AM Bendele","year":"1998","unstructured":"Bendele, A. M. Urologic syndrome, mouse. In Urinary System. Monographs on Pathology of Laboratory Animals (eds Jones, T. C. et al.) 456\u2013462 (Springer, 1998)."},{"key":"32641_CR37","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1111\/ejn.15382","volume":"55","author":"DLE Vergoossen","year":"2021","unstructured":"Vergoossen, D.L.E., Keo, A., Mahfouz, A. & Huijbers, M.G. Timing and localization of myasthenia gravis-related gene expression. Eur. J. Neurosci. 55, 5574\u20135585 (2021).","journal-title":"Eur. J. Neurosci."},{"key":"32641_CR38","first-page":"2166","volume":"1834","author":"SR Hubbard","year":"2013","unstructured":"Hubbard, S. R. & Gnanasambandan, K. Structure and activation of MuSK, a receptor tyrosine kinase central to neuromuscular junction formation. Biochem. Biophys. Acta 1834, 2166\u20132169 (2013).","journal-title":"Biochem. Biophys. Acta"},{"key":"32641_CR39","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1073\/pnas.080061997","volume":"97","author":"A Watty","year":"2000","unstructured":"Watty, A. et al. The in vitro and in vivo phosphotyrosine map of activated MuSK. Proc. Natl. Acad. Sci. USA 97, 4585\u20134590 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32641_CR40","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/srep13928","volume":"5","author":"K Otsuka","year":"2015","unstructured":"Otsuka, K. et al. Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling. Sci. Rep. 5, 13928. https:\/\/doi.org\/10.1038\/srep13928 (2015).","journal-title":"Sci. Rep."},{"key":"32641_CR41","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.mcpro.2022.100221","volume":"21","author":"HG Budayeva","year":"2022","unstructured":"Budayeva, H. G. et al. Phosphoproteome profiling of the receptor tyrosine kinase MuSK identifies tyrosine phosphorylation of Rab GTPases. Mol. Cell Proteom. 21, 100221. https:\/\/doi.org\/10.1016\/j.mcpro.2022.100221 (2022).","journal-title":"Mol. Cell Proteom."},{"key":"32641_CR42","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","volume":"317","author":"MG Huijbers","year":"2019","unstructured":"Huijbers, M.G., et al. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp. Neurol. 317, 133\u2013143 (2019).","journal-title":"Exp. Neurol."},{"key":"32641_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.expneurol.2011.04.018","volume":"230","author":"AR Punga","year":"2011","unstructured":"Punga, A. R., Lin, S., Oliveri, F., Meinen, S. & R\u00fcegg, M. A. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Exp. Neurol. 230, 207\u2013217 (2011).","journal-title":"Exp. Neurol."},{"key":"32641_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1460-9568.2010.07569.x","volume":"33","author":"AR Punga","year":"2011","unstructured":"Punga, A. R., Maj, M., Lin, S., Meinen, S. & R\u00fcegg, M. A. MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity. Eur. J. Eurosci. 33, 890\u2013898 (2011).","journal-title":"Eur. J. Eurosci."},{"key":"32641_CR45","first-page":"369","volume-title":"Urinary System. Monographs on Pathology of Laboratory Animals","author":"AM Bendele","year":"1998","unstructured":"Bendele, A. M. & Carlton, W. W. Urologic syndrome, mouse. In Urinary System. Monographs on Pathology of Laboratory Animals (eds Jones, T. C. et al.) 369\u2013375 (Springer, 1998)."},{"key":"32641_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJGM.S88552","volume":"9","author":"R Mantegazza","year":"2016","unstructured":"Mantegazza, R., Cordiglieri, C., Consonni, A. & Baggi, F. Animal models of myasthenia gravis: Utility and limitations. Int. J. Gen. Med. 9, 53\u201364 (2016).","journal-title":"Int. J. Gen. Med."},{"key":"32641_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga, A. R., Maddison, P., Heckmann, J. M., Guptill, J. T. & Evoli, A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 21, 176\u2013188 (2022).","journal-title":"Lancet Neurol."},{"key":"32641_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","volume":"120","author":"UK Misra","year":"2020","unstructured":"Misra, U. K., Kalita, J., Sing, V. K. & Kumar, S. A study of comorbidities in myasthenia gravis. Acta Neurol. Belg. 120, 59\u201364 (2020).","journal-title":"Acta Neurol. Belg."},{"key":"32641_CR49","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.21037\/jtd.2018.04.95","volume":"10","author":"B Cacho-D\u00edaz","year":"2018","unstructured":"Cacho-D\u00edaz, B., Salmer\u00f3n-Moreno, K., Lorenzana-Mendoza, N. A., Texcocano, J. & Arrieta, O. Myasthenia gravis as a prognostic marker in patients with thymoma. J. Thorac. Dis. 10, 2842\u20132848 (2018).","journal-title":"J. Thorac. Dis."},{"key":"32641_CR50","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1159\/000514825","volume":"13","author":"F Tateno","year":"2021","unstructured":"Tateno, F., Sakakibara, R. & Aiba, Y. Lower urinary tract symptoms in myasthenia gravis. Case Rep. Neurol. 13, 490\u2013498 (2021).","journal-title":"Case Rep. Neurol."},{"key":"32641_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","volume":"291","author":"MG Huijbers","year":"2016","unstructured":"Huijbers, M. G. et al. Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity. J. Neuroimmunol. 291, 82\u201388 (2016).","journal-title":"J. Neuroimmunol."},{"key":"32641_CR52","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1111\/j.1476-5381.2010.01115.x","volume":"162","author":"MK Sadegh","year":"2011","unstructured":"Sadegh, M. K. et al. Biomechanical properties and innervation of the female caveolin-1-deficient detrusor. Br. J. Pharmacol. 162, 1156\u20131170 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"32641_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1254\/jphs.FM0070115","volume":"106","author":"M Yoshida","year":"2008","unstructured":"Yoshida, M. et al. Basic and clinical aspects of non-neuronal acetylcholine: Expression of non-neuronal acetylcholine in urothelium and its clinical significance. J. Pharmacol. Sci. 106, 193\u2013198 (2008).","journal-title":"J. Pharmacol. Sci."},{"key":"32641_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1258\/002367785780893566","volume":"19","author":"DM Taylor","year":"1985","unstructured":"Taylor, D. M. Urethral plugs and urine retention in male mice. Lab. Anim. 19, 189\u2013191 (1985).","journal-title":"Lab. Anim."},{"key":"32641_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1258\/002367782781110205","volume":"16","author":"I Kunstyr","year":"1982","unstructured":"Kunstyr, I., K\u00fcpper, W., Weisser, H., Naumann, S. & Messow, C. Urethral plug\u2014a new secondary male sex characteristics in rat and other rodents. Lab. Anim. 16, 151\u2013155 (1982).","journal-title":"Lab. Anim."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32641-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32641-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T20:02:00Z","timestamp":1683576120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32641-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32641"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32641-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G.H., J.J.P., S.M.M. and J.J.V. are co-inventors on two patent applications on MuSK-related research. LUMC, M.G.H., J.J.P., S.M.M. and J.J.V. receive license income from these patents. LUMC receives royalties for a diagnostic MuSK ELISA. C.S., C.B., R.V., and K.S., are (former) employees\/consultants of argenx BV and some are holders of employee equity in argenx SE. Argenx exclusively owns two patent families which have been filed by applicant \u2018Academisch Ziekenhuis Leiden (h.o.d.n. LUMC)\u2019. The two patent families WO2020\/055241 and WO2020\/055240 are directed to respectively agonistic and antagonistic antibodies binding to Ig-like 1 domain of MuSK. \u2018argenx IIP BV\u2019 and \u2018Academisch Ziekenhuis Leiden\u2019 are co-applicants on a patent family (WO2021\/180676) directed to antibodies binding to Ig-like 1 domain of MuSK, and therapeutic uses thereof. No other authors have conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7478"}}